STAT+: Psilocybin’s lasting benefits prove elusive in mice

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Wishing you a colorful Día de los Muertos. Remembering my grandmother, in particular, a zoology professor who sparked my penchant for all things biological. Her dissertation was on shrimp chromatophores, I believe. The need-to-know this morning UniQure said the Food and Drug Administration accepted the marketing application for its AMT-130 gene therapy to treat Huntington’s disease. The approval decision date is May 1, 2027. The FDA is “tentatively planning” an advisory committee meeting to review the AMT-130 data, the company said. Scant evidence for a next-gen, destination IVF business A fertility treatment framed as a way to rewind the biological clock has spawned an international medical tourism business — with precious little evidence to back it up. An eight-month STAT investigation found clinics and middlemen marketing mitochondrial replacement, or “three-parent IVF,” to older women willing to spend tens of thousands of dollars for a shot at a genetically related child. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe